Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

490
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
490
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

398
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
398
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

373
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
373
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

333
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of the drug-induced cholestasis index based on advanced modeling for predicting liver toxicity.

Toxicology·2025
Same author

Pubic Arch Angle Postural Mobility Evaluation in Different Patient's Positions for Clinical Research.

Cureus·2025
Same author

Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy.

CPT: pharmacometrics & systems pharmacology·2024
Same author

DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapy.

NPJ systems biology and applications·2024
Same author

Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy.

British journal of clinical pharmacology·2024
Same author

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.

Pharmaceutics·2023

Related Experiment Video

Updated: May 3, 2026

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

1.8K

Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.

Darren Michael Moss1, Marco Siccardi

  • 1Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

British Journal of Pharmacology
|January 29, 2014
PubMed
Summary

Nanomedicine enhances drug delivery but faces challenges in absorption and distribution. Physiologically based pharmacokinetic (PBPK) modeling is emerging as a tool to understand nanoformulation behavior and optimize treatments.

Keywords:
ADMEPBPKnanoformulationnanoparticleoptimizationpharmacokinetics

More Related Videos

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.4K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.3K

Related Experiment Videos

Last Updated: May 3, 2026

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

1.8K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.4K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.3K

Area of Science:

  • Pharmacology and Nanotechnology
  • Drug Delivery Systems

Background:

  • Therapeutic agent delivery faces challenges like poor absorption, low tissue penetration, and organ toxicity.
  • Nanomedicine offers advanced strategies to improve drug delivery and disease treatment outcomes.
  • Understanding nanoformulation pharmacokinetics (ADME) is crucial, as it differs significantly from traditional drugs.

Purpose of the Study:

  • To review current knowledge on nanomedicine distribution.
  • To explore the application of physiologically based pharmacokinetic (PBPK) modeling in nanomedicine.
  • To highlight the potential of PBPK models in characterizing nanoformulations for optimal pharmacokinetics.

Main Methods:

  • Literature review of nanomedicine distribution and PBPK modeling applications.
  • Discussion of challenges and opportunities in applying PBPK to nanoformulations.
  • Integration of property-distribution relationships within PBPK frameworks.

Main Results:

  • Physiologically based pharmacokinetic (PBPK) modeling is a valuable tool for simulating nanoformulation distribution.
  • PBPK models integrate in vitro nanoparticle data with physiological information to predict ADME.
  • Understanding property-distribution relationships is key to advancing PBPK applications in nanomedicine.

Conclusions:

  • PBPK modeling is an emerging but promising approach for characterizing nanoformulation pharmacokinetics.
  • This modeling can enhance the understanding of nanoformulation disposition mechanisms.
  • PBPK modeling facilitates the rapid and accurate determination of nanoformulation kinetics for improved therapeutic strategies.